Trial Profile

Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oritavancin (Primary)
Indications Bacteraemia; Infectious arthritis; Osteomyelitis; Skin and soft tissue infections
Focus Therapeutic Use
Acronyms AIM-STOP

29 May 2025 Status changed from recruiting to discontinued as the study was not able to enroll adequate participants within predetermined timelines
09 Jul 2024 Planned End Date changed from 1 May 2025 to 31 Dec 2025.
09 Jul 2024 Planned primary completion date changed from 1 Mar 2025 to 30 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com